Interferon gamma in the pathogenesis of hypertension − recent insights
Lance N. Benson,Shengyu Mu
DOI: https://doi.org/10.1097/mnh.0000000000000966
2024-01-20
Current Opinion in Nephrology & Hypertension
Abstract:Research investigating the potentially causative link between the immune system and hypertension has flourished in the last twenty years as reports from numerous labs across the globe continued to indicate a pathogenic contribution of immunity to the development, maintenance, and pathology of elevated blood pressure [1–5,6▪,7] . Studies into the critical contributions of T cells [3,4,7,8] , macrophages [9–12] , and dendritic cells [13–17] have proven especially illuminating as a variety of overlapping mechanisms have begun to emerge [18] , especially within the kidney. Depletion of any of these immune cell populations ameliorates the blood pressure response to a hypertensive pressor [3,19–22] . Through identifying these inflammatory pathways, researchers have begun to unravel the preeminent role of the cytokine interferon gamma (IFNγ) in mediating disease progression [2,6▪,14,23,24▪,25,26] . Deficiency of this 25 kDa cytokine has been found to protect against hypertension in the DOCA + salt and angiotensin II models by attenuating the upregulation of renal sodium transporters and preventing T cell accumulation in the kidneys [6▪,23,27] . However, the consequence of IFNγ deficiency on the progression of hypertension may vary between models. Even though knockout of IFNγ blunted blood pressure elevation and reduced renal immune cell accumulation in several mouse models of hypertension [6▪,23,27] , cardiac hypertrophy, diastolic dysfunction, and myocardial autophagy were reported to be worsened in a mouse IFNγ knockout (KO) aldosterone infusion model despite the lower blood pressure [28] . Supplementing with recombinant IFNγ protected against worsened cardiac hypertrophy [28] . In the same year, infusion of angiotensin II into IFNγ-receptor KO mice resulted in reduced cardiac hypertrophy, reduced cardiac immune cell accumulation, and reduced fibrosis compared to angiotensin II-infused WT mice [23] . Additional prudence, then, is warranted when discussing IFNγ-related mechanisms. Several recent preclinical studies have continued to uncover the molecular mechanisms by which IFNγ mediates the progression of cardiovascular diseases [6▪,24▪,29▪▪,30▪▪,31▪,32▪] , and several recent clinical studies corroborate, at minimum, a correlation between IFNγ and elevated systolic blood pressure [33▪,34▪▪,35▪] . This review will highlight these recent findings from the last two years and discuss them in the context of presently understood mechanisms. For information regarding the upstream and downstream signaling mechanisms of IFNγ, we refer the readers to these reviews by Bhat et al. [36] and Schroder et al. [37]
peripheral vascular disease,urology & nephrology